title: Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
authors: Raffaele
authors: R
authors: Bruno
authors: Stefano
authors: S
authors: Fagiuoli
authors: Paolo
authors: P
authors: Sacchi
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D060085:Coinfection; D004347:Drug Interactions; D006678:HIV / Q000187:drug effects* / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology; D016174:Hepacivirus / Q000187:drug effects* / Q000201:enzymology; D006526:Hepatitis C / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use; D011392:Proline / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D057057:Serine Proteases / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D014764:Viral Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D015842:Serine Proteinase Inhibitors; D014764:Viral Proteins; D012254:Ribavirin; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D007372:Interferons; D011392:Proline; D057057:Serine Proteases